BAD
MOLECULAR TARGETBCL2 associated agonist of cell death
BAD (BCL2 associated agonist of cell death) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting BAD
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gossypol | 4.42 | 82 |
| 2 | abt 737 | 4.04 | 56 |
| 3 | venetoclax | 3.69 | 39 |
| 4 | navitoclax | 3.53 | 33 |
| 5 | sanguinarium | 3.40 | 29 |
| 6 | chelerythrine chloride | 3.04 | 20 |
| 7 | obatoclax | 2.08 | 7 |
| 8 | egcg | 0.69 | 1 |
About BAD as a Drug Target
BAD (BCL2 associated agonist of cell death) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented BAD interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
BAD inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.